Status:
COMPLETED
Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Conditions:
Parkinson's Disease
Eligibility:
All Genders
35+ years
Phase:
PHASE3
Brief Summary
Patients who completed the study TVP-1012/232 are eligible to enter the extension study to continue their rasagiline therapy for their Parkinson's disease (PD). During this study the patient's safety,...
Eligibility Criteria
Inclusion
- • Patients who completed evaluations of week 52 of the TVP 1012/232 protocol, where continued rasagiline therapy is warranted, in the opinion of the principal investigator
Exclusion
- • Patients having suffered adverse effects that were probably drug-related in the TVP-1012/232 study
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
306 Patients enrolled
Trial Details
Trial ID
NCT00203138
Start Date
June 1 2004
End Date
December 1 2006
Last Update
April 12 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.